Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

RCT (n=171) found clinical outcomes were not improved by ALX-0171, a novel trivalent nanobody with antiviral properties against RSV, vs. placebo, with no difference in time to clinical response or change in the global severity score from baseline to 5 hours post-dose on day 2.

Source:

The Lancet Respiratory Medicine